One-year outcomes with the Taxus Liberté stent in the real world: the Taxus Olympia registry (phase I).
BACKGROUND
The Taxus Olympia registry is a prospective, postapproval registry collecting clinical outcomes data on patients receiving the Taxus Liberté paclitaxel-eluting stent during routine interventional cardiology practice.


METHODS
Between February and July 2005, 529 patients receiving the Taxus Liberté stent at 16 centers in the Middle East, South/Central America, and Asia/Pacific regions were enrolled in Phase I of Olympia. The primary end-point was Taxus Liberté stent-related cardiac events (cardiac death, MI, and revascularization) at 30 days postimplant. Additional clinical assessment was conducted at 6 and 12 months. Olympia phases II and III are in clinical follow-up and will be reported separately.


RESULTS
One-year clinical follow-up is available for 98% of patients. Complex patients and lesions were prevalent, including: 50% diabetes mellitus, 49% multivessel disease, 30% multiple stenting, 48% AHA/ACC type B2/C lesions, 19% long lesions (>26 mm), and 40% small vessels (<or=2.75 mm). At 1 year, the cardiac event rate was 4.1%, including 1.5% cardiac death, 1.5% MI, and 2.3% target vessel revascularization (TVR). The TAXUS Liberté stent-related cardiac event rate was 3.7% at 1 year. Stent thrombosis (ST) occurred in 1.7% of patients, with three cases occurring >30 days postprocedure. One-year cardiac event rates among complex subpopulations (diabetics 5.0%, multiple stents 3.8%, long lesions 3.1%, and small vessels 2.9%) were comparable to the overall study population.


CONCLUSIONS
In conclusion, this first report of real-world experience with the Taxus Liberté stent demonstrates the safety and clinical utility of this stent in the broader spectrum of coronary disease treated in everyday practice.
Ahmed
Waqar Habib
WH
Armed Forces Hospital, Jeddah, Saudi Arabia. waqar@post.harvard.edu
Zambahari
Robaayah
R
Al-Rashdan
Ibrahim
I
Al Naeemi
Abdullah
A
Saeed
Fuad A
FA
Mascioli
Stephen
S
D000328:Adult; D000368:Aged; D000800:Angioplasty, Balloon; D015906:Angioplasty, Balloon, Coronary / Q000379:methods / Q000706:statistics & numerical data*; D001208:Asia / Q000453:epidemiology; D006328:Cardiac Catheterization; D002489:Central America / Q000453:epidemiology; D003324:Coronary Artery Disease / Q000401:mortality / Q000628:therapy*; D023903:Coronary Restenosis / Q000517:prevention & control; D054855:Drug-Eluting Stents / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008877:Middle East / Q000453:epidemiology; D009203:Myocardial Infarction / Q000401:mortality; D009204:Myocardial Revascularization / Q000379:methods / Q000706:statistics & numerical data*; D017239:Paclitaxel / Q000008:administration & dosage*; D011358:Product Surveillance, Postmarketing; D011446:Prospective Studies; D012042:Registries; D013020:South America / Q000453:epidemiology; D020946:Taxus; D016896:Treatment Outcome; D050257:Tubulin Modulators / Q000008:administration & dosage*
D050257:Tubulin Modulators; D017239:Paclitaxel